Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® inhaler versus MDI

Respiratory Medicine

Volumn 104, Issue 8, 2010, Pages 1179-1188

  ZuWallack, R ^a   De Salvo, M C ^b   Kaelin, T ^c   Bateman, E D ^d   Park, C S ^e   Abrahams, R ^f   Fakih, F ^g   Sachs, P ^h   Pudi, K ⁱ   Zhao, Y ^j   Wood, C C ^j  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b Centro Medico Dra de Salvo   (Argentina)

^c Lowcountry Lung and Critical Care PA   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e Soonchunhyang University   (South Korea)

^f Morgantown Pulmonary Clinical Research   (United States)

^g Florida Pulmonary Research Center   (United States)

^h Pulmonary Associates of Stamford   (United States)

ⁱ Upstate Pharmaceutical Research   (United States)

^j BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

more..

Author keywords

Anticholinergic; Bronchodilator; COPD; Ipratropium bromide; Respimat inhaler

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; METHYLXANTHINE DERIVATIVE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SPIROMETRY; TREMOR; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADMINISTRATION, INHALATION; ALBUTEROL; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 77953913121     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.01.017     Document Type: Article

References (24)

1. ® Soft Mist™ Inhaler and pressurized metered dose inhalers. J Aerosol Med 18 (2005) S273-S282
2. ®. J Aerosol Med 12 Suppl. 1 (1999) S19-S24
3. Newman S.P., Steed K.P., Reader S.J., Hooper G., and Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 85 (1996) 960-964
4. Newman S.P., Brown J., Steed K.P., Reader S.J., and Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest 113 (1998) 957-963
5. ® dry powder inhaler. J Aerosol Med 18 (2005) S264-S272
6. Bone R., Boyars M., Braun S.R., et al., for the Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 105 (1994) 1411-1419
7. Dorinsky P.M., Reisner C., Ferguson G.T., Menjoge S.S., Serby C.W., and Witek Jr. T.J. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with chronic obstructive pulmonary disease. Chest 115 (1999) 966-971
8. Chrischilles E., Gilden D., Kubisiak J., Rubenstein L., and Shah H. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care 8 (2002) 902-911
9. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 152 (1995) 1107-1136
10. Miller M.R., Hankinson J., Brusasco V., et al. Standardisation of spirometry. Eur Respir J 26 (2005) 319-338
11. "Data on file, Boehringer-Ingelheim".
12. "Data on file, Boehringer-Ingelheim".
13. "Data on file, Boehringer-Ingelheim".
14. Tashkin D.P., Celli B., Senn S., et al., for the UPLIFT study investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
15. Calverley P.M.A., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al., for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
16. Calverley P., Pauwels R., Vestbo J., et al., for The TRISTAN Study Group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
17. Wedzicha J.A., Calverley P.M., Seemungal T.A., Hagan G., Ansari Z., Stockley R.A., and for the INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008) 19-26
18. "Data on file, Boehringer-Ingelheim".
19. Schürmann W., Schmidtmann S., Moroni P., Massey D., and Qidan M. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med 4 (2005) 53-61
20. Hodder R.V., Schurmann W., Moroni P., and Barczok M. Patients with obstructive lung disease prefer Respimat Soft Mist(TM) inhaler to pMDI. Chest 126 (2004) 806s
21. Kozma C.M., Slaton T.L., Monz B.U., Hodder R., and Reese P.R. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med 4 (2005) 41-52
22. "Data on file, Boehringer-Ingelheim".
23. "Data on file, Boehringer-Ingelheim".
24. ® Soft Mist™ inhaler in patients with COPD. Respir Med 98 (2004) 387-397